We performed a post hoc analysis of data pooled from three randomized , placebo - and active-controlled , phase III studies of tapentadol ER for managing chronic osteoarthritis knee ( NCT00421928 , NCT00486811 ) or low back ( NCT00449176 ) pain ( 15-week , double-blind treatment period ) .